logo
Insurance co, docs told to pay Rs 3L to woman after C-section trauma

Insurance co, docs told to pay Rs 3L to woman after C-section trauma

Time of India06-05-2025
Ghaziabad: The district consumer disputes redressal commission (DCDRC) directed an insurance company to pay Rs 2.8 lakh to a patient who underwent a caesarean section at a local hospital in 2014 but faced severe complications due to doctors' negligence. The commission also ordered the doctors to pay Rs 20,000 as damages for physical and mental trauma, besides the cost of litigation.The petitioner, Varsha Singh, informed the commission that she was in labour when doctors Santosh Agrawal and Vinita Agrawal left her in that condition for three hours to take part in a marriage ceremony. The victim alleged that the delay in attending to her resulted in complications, forcing her to undergo a caesarean section for delivery at the Shyam Hospital, Ghaziabad. Her condition, however, deteriorated over time, and she remained under treatment for over a month, the woman told the commission.The woman informed the forum that persistent abdominal pain and bloating forced the family to consult another doctor at Madhu Nursing Home in Meerut on August 13, 2015.Upon checkup, it was found that a sponge was left inside her stomach at the time of delivery, causing septic infection of the intestine."When the abdominal pain and bloating did not subside, we consulted another doctor, who diagnosed a sponge left in my stomach that resulted in a septic infection of the intestine," Singh informed the commissionProducing records of the hospital bills and reated documents, Singh informed the commission that she underwent another surgery to remove a part of her intestine and clean the infection.Taking note of the evidence and medical records produced, chairman of the commission, Praveen Kumar Jain, decided in favour of the petitioner and held New India Assurance Company Limited accountable for payment of the entire sum on behalf of the erring doctors, as Shyam Hospital was fully insured by the insurance company.Not only the commission held the doctors responsible for showing medical negligence, the forum also rejected the insurance company's argument that they were not informed at the time of admission of the patient and that it violated section 8.1 of policy."The petitioners have made the insurance company a party in the case, which is sufficient to hold that the company was informed well within the time," stated the commission in its order.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Farmer dies by suicide, family blames crop failure
Farmer dies by suicide, family blames crop failure

Time of India

timean hour ago

  • Time of India

Farmer dies by suicide, family blames crop failure

Balangir: A 46-year-old farmer died on Thursday after allegedly consuming poison with family members blaming crop failure and mounting debt for his death. The incident occurred in Kandara village under Titilagarh block of Balangir district. Tired of too many ads? go ad free now The deceased, Durga Charan Bhoi, had been under severe mental stress after failing to repay multiple loans, his family claimed. Bhoi allegedly took pesticide on Wednesday afternoon. Family members found him unconscious behind their house and took him to Sindhekela hospital, before he was shifted to Titilagarh hospital. As his condition worsened, he was moved to the district headquarters hospital in Bhawanipatna, where doctors pronounced him dead. Bhaskar Bhoi, the deceased's cousin, said, "My brother had borrowed over Rs 2 lakh from various self-help groups and banks for paddy and cotton cultivation. Crop failure made repayment impossible." Bhoi had cultivated paddy on 3 acres and cotton on 2 acres of land. Family members claimed the crops got damaged due to scanty rainfall. On Thursday, police launched a probe while senior revenue and agriculture officials met the bereaved family. The administration provided Rs 10,000 as immediate assistance and promised additional compensation as per govt provisions. Titlagarh tehsildar Subhashis Satapathy said, "We will conduct a thorough ground inquiry and take appropriate action based on our findings."

Allahabad HC stays fee hike for MBBS course by Hapur medical college
Allahabad HC stays fee hike for MBBS course by Hapur medical college

News18

time2 hours ago

  • News18

Allahabad HC stays fee hike for MBBS course by Hapur medical college

Agency: PTI Prayagraj, Aug 14 (PTI) The Allahabad High Court has stayed an increase in fee for the MBBS course by the GS Medical College in Hapur, and directed the state government and the college to file their reply within two weeks. The order was passed by Justice C D Singh on August 13 while hearing a petition filed by Aanya Porwal and 239 other MBBS students. The fee was increased mid-semester from Rs 11 lakh to 14 lakh. The counsel for the petitioners claimed the notification issued on July 5 by the state government was 'arbitrary" and 'without application of mind". The government, while issuing the aforesaid notification, failed to consider the other miscellaneous charges, which have already been enhanced during this session, the counsel argued. He said there was no reason to increase the fee for a second time in eight months, particularly when miscellaneous charges had already been deposited by the petitioners. The government's counsel submitted that it (fee hike) was done in accordance with the law, and there was no illegality or error in the impugned notification, saying the instant writ petition may be dismissed as devoid of any merit. The court said, 'Taking into consideration the submissions made by the learned counsel for the petitioners as well as the learned counsel for the respondent and the contents made in the writ petition, I am of the view that matter requires consideration." The court directed to put up the case on September 17, and till then the operation of the impugned notification dated July 5 shall be kept in abeyance. PTI COR RAJ ARI view comments First Published: August 14, 2025, 23:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

AstraZeneca Pharma India's net profit slips 4 pc in Q1
AstraZeneca Pharma India's net profit slips 4 pc in Q1

Hans India

time6 hours ago

  • Hans India

AstraZeneca Pharma India's net profit slips 4 pc in Q1

Mumbai: AstraZeneca Pharma India Limited on Thursday reported a 4.12 per cent decline in net profit for the first quarter (Q1) of FY26, with earnings falling to Rs 55.8 crore from Rs 58.2 crore in the previous quarter (Q4 FY25). This dip came despite a strong rise in revenue from operations, which grew 9.56 per cent sequentially to Rs 526.3 crore from Rs 480.4 crore, according to its stock exchange filing. Other income saw a sharp decline of 30.43 per cent, dropping to Rs 11.2 crore from Rs 16.1 crore in Q4 FY25. However, total income rose 8.23 per cent to Rs 537.5 crore from Rs 496.6 crore, driven by solid operational performance. Total expenses increased by 12.12 per cent to Rs 462.4 crore, compared to Rs 412.4 crore in the previous quarter, the company stated in its regulatory filing. Bhavana Agrawal, Chief Financial Officer and Director of the Company, said the strong quarterly performance reflects the power of science-led innovation combined with disciplined execution. 'Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most,' she added. Praveen Rao Akkinepally, Country President and Managing Director, said that delivering consistent growth across therapy areas reaffirms the strength of the company's 'Growth Through Innovation' strategy. 'These results are a testament to what is possible when science and purpose come together,' he noted. AstraZeneca, a global science-led biopharmaceutical company, focuses on the discovery, development, and commercialisation of prescription medicines, primarily in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases. The company operates in over 100 countries, with its medicines used by millions of patients worldwide. Completing 45 years in India, AstraZeneca Pharma India Limited is headquartered in Bengaluru and employs over 600 people across the country.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store